Atamyo Therapeutics
- Address
- 1 B Rue De L Internationale
Sponsor Overview
Specializations
Muscular Dystrophy
Atamyo Therapeutics focuses on inherited muscle disorders within the limb-girdle muscular dystrophy spectrum, with clinical work centered on FKRP-related limb-girdle muscular dystrophy and limb-girdle muscular dystrophy type R5.
- LGMDR9
- LGMDR5
- Inherited myopathy
The sponsor’s clinical portfolio is directed toward neuromuscular conditions affecting mobility and skeletal muscle function in ambulant patients.
Gene Therapy
The company’s research activity is concentrated in gene therapy for rare neuromuscular disease, with programs built around intravenous administration of therapeutic genetic constructs.
- ATA-100
- ATA-200
- Genetic medicine
Its clinical interests include treatment approaches intended to address the underlying genetic basis of muscular dystrophy.
Pediatric Neuromuscular Care
Atamyo Therapeutics is involved in studies involving pediatric patients with ambulant forms of limb-girdle muscular dystrophy, reflecting attention to early-life manifestations of neuromuscular disease.
- Pediatric patients
- Ambulatory function
- Rare disease pediatrics
Its research landscape includes clinical interest in preserving movement and muscle performance in younger patient populations.
Rare Disease Clinical Development
The sponsor’s trial activity is concentrated in rare disease development for genetically defined neuromuscular disorders, with active studies across multiple countries and collaborating sites.
- Orphan disease research
- Multinational clinical development
- Neuromuscular genetics
Its clinical research portfolio is organized around genetically targeted treatment options for distinct subtypes of limb-girdle muscular dystrophy.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 1-2 Multicenter Study on Safety and Efficacy of Intravenous GNT0006 in FKRP-Related Limb-Girdle Muscular Dystrophy (LGMDR9) Patients |  Denmark France | Not Recruiting |
| Phase I/II Open-Label Study Evaluating Safety of Intravenous ATA-200 Gene Therapy in Pediatric Patients with Limb-Girdle Muscular Dystrophy Type R5 | France Italy | Not Yet Recruiting |
Data & Insights
This sponsor works with 6 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 4 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases2 trials238 other sponsors
Partnered Research Centres
4 centres- Address
- Batiment Babinski Groupe 47 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Via Francesco Sforza 28, 20122 Milan
- Address
- Blegdamsvej 9, 2100 Copenhagen
- Address
- 47 To 83 Boulevard De L Hopital, 75013 Paris
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Atamyo Therapeutics.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.